Ultragenyx Pharmaceutical Inc. (RARE)
Nasdaq: RARE · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 2011
Filings
374 filings since 2017 beside 515 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Mar 1, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 34 days after the quarter ended. The proxy statement was last filed Mar 27, 2026.
Filings a yearinsider forms included
113128916177835895
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 3 times in the last 36 months, the newest May 18, 2026.SEC letters: 3 in the last 36 months, the newest Jun 10, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 3, 2026
8-K items 2.01, 2.02, 2.05, 9.01
Purchase or sale of a business completed; Results released; Exit or restructuring costs · Current report
Oct 30, 2026
May 18, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
May 14, 2026
Feb 12, 2026
8-K items 2.02, 2.05, 9.01
Results released; Exit or restructuring costs · Current report
40 of 374 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.